2018 American Transplant Congress
Impact of Early Corticosteroid Treatment in Patients with Indeterminate Acute Severe Hepatitis
Background and Aims: Discrimination of acute severe autoimmune hepatitis AIH and drug induced liver injury in patients with indeterminate acute severe Hepatitis is challenging. Early…2017 American Transplant Congress
Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study.
Hepatitis E virus (HEV) is responsible for acute and chronic autochthonous hepatitis in developed countries, particularly in Western Europe. Conversely to hepatitis B or C,…2017 American Transplant Congress
Risk Factor for Hepatitis E Virus Infection Among Solid-Organ-Transplant Patients.
Genotype 3 and 4 hepatitis E virus (HEV) infections are prevalent in developed countries and can cause chronic hepatitis, cirrhosis, and extra-hepatic manifestations among solid-organ-transplant…2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…2016 American Transplant Congress
Long Term Outcome of De-Novo Autoimmune Hepatitis in Pediatric Recipients of Liver Transplantation.
Background: De-novo autoimmune hepatitis (DAIH) is a chronic immune mediated graft disorder seen following liver transplantation (LT). The long-term course and outcome of DAIH is…2016 American Transplant Congress
Review of Organ Utilization from Increased Infectious Risk Donors.
IntroductionDonors with an increased risk of transmitting HIV, HBV or HCV (IRDs) are a potential source of organs. There is a lack of data on…2015 American Transplant Congress
The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis
The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective…
American Transplant Congress abstracts